{
  "case_id": "MN22-37832",
  "year": 2022,
  "patient_info": {
    "age_range": "51 to 64",
    "gender": "Male"
  },
  "diagnosis": "Immuno Disorders",
  "secondary_conditions": [],
  "complications": [],
  "symptoms": [
    "inflammatory arthritis",
    "malar rash",
    "hypocomplementemia"
  ],
  "treatment_category": "Pharmacy",
  "treatment_subcategory": "Biologics",
  "treatments_requested": [
    {
      "name": "Benlysta",
      "drug_type": "biologic",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    }
  ],
  "treatments_tried_but_failed": [
    {
      "name": "Steroids",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Antimalarials",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Immunosuppressive Therapy with Methotrexate",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    }
  ],
  "treatments_tried_and_worked": [],
  "treatments_not_tried": [
    {
      "name": "Cyclophosphamide",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "Rituximab",
      "drug_type": "biologic",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    },
    {
      "name": "IVIG",
      "drug_type": "standard",
      "procedure_type": null,
      "is_procedure": false,
      "other_or_notes": null
    }
  ],
  "is_denial_upheld": false,
  "issues_considered": [
    "medical_necessity"
  ],
  "other_issues": null,
  "guidelines_support": true,
  "guidelines_not_support": null,
  "guidelines_details": "Robust evidence from randomized clinical studies and observational, real-world studies has demonstrated the tolerability and efficacy of belimumab for reducing disease activity and the risk of new, severe SLE flares.",
  "soc_support": true,
  "soc_not_support": null,
  "soc_details": "Belimumab has established its position as a disease modifier in the SLE treatment paradigms.",
  "study_support": true,
  "study_details": [
    {
      "study_name": "Pisetsky and Lipsky",
      "study_authors": "Pisetsky and Lipsky",
      "key_findings": "Many patients with SLE are ANA negative at screening. Limitations in the ANA assays or a transition in some patients to a serologically negative state may explain ANA negativity in persons with true SLE."
    },
    {
      "study_name": "Levy and colleagues",
      "study_authors": "Levy and colleagues",
      "key_findings": "Belimumab has established its position as a disease modifier in the SLE treatment paradigms."
    }
  ],
  "key_questions": [
    "medical_necessity"
  ],
  "expedited": true,
  "rationale": "The requested medication is medically necessary for treatment of the patient\u2019s medical condition. The Health Plan\u2019s denial should be overturned.",
  "reviewer_credentials": "Board certified in internal medicine with sub-specialty certification in rheumatology and actively practicing."
}